| Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised … JP Neoptolemos, DH Palmer, P Ghaneh, EE Psarelli, JW Valle, ... The Lancet 389 (10073), 1011-1024, 2017 | 1888 | 2017 |
| Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study JN Primrose, RP Fox, DH Palmer, HZ Malik, R Prasad, D Mirza, A Anthony, ... The Lancet Oncology 20 (5), 663-673, 2019 | 992 | 2019 |
| Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial RP Jones, EE Psarelli, R Jackson, P Ghaneh, CM Halloran, DH Palmer, ... JAMA surgery 154 (11), 1038-1048, 2019 | 188 | 2019 |
| Interventions for the treatment of borderline ovarian tumours O Faluyi, M Mackean, C Gourley, A Bryant, HO Dickinson Cochrane Database of Systematic Reviews, 2010 | 79 | 2010 |
| European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC … JP Neoptolemos, DH Palmer, P Ghaneh, EE Psarelli, JW Valle, ... Lancet 389 (10073), 1011-1024, 2017 | 66 | 2017 |
| Breast radiotherapy for occult breast cancer with axillary nodal metastases—does it reduce the local recurrence rate and increase overall survival? SP Masinghe, OO Faluyi, GR Kerr, IH Kunkler Clinical Oncology 23 (2), 95-100, 2011 | 58 | 2011 |
| TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial DH Palmer, JW Valle, YT Ma, O Faluyi, JP Neoptolemos, ... British journal of cancer 122 (7), 971-977, 2020 | 36 | 2020 |
| Regulation of stromal cell cyclooxygenase-2 in the Apc Min/+ mouse model of intestinal tumorigenesis MA Hull, OO Faluyi, CWS Ko, S Holwell, DJ Scott, RJ Cuthbert, ... Carcinogenesis 27 (3), 382-391, 2006 | 34 | 2006 |
| Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment L Dodbiba, J Teichman, A Fleet, H Thai, B Sun, D Panchal, D Patel, A Tse, ... Laboratory investigation 93 (4), 397-407, 2013 | 33 | 2013 |
| Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in Oncology patients with renal impairment OO Faluyi, SP Masinghe, RL Hayward, S Clive Medical Oncology 29, 755-760, 2012 | 24 | 2012 |
| Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: a new application for the hepatoma arterial embolisation prognostic score J Edeline, JF Blanc, B Campillo-Gimenez, YT Ma, J King, O Faluyi, ... European Journal of Cancer 86, 135-142, 2017 | 21 | 2017 |
| Observational study to assess quality of life in patients with pancreatic neuroendocrine tumors receiving treatment with everolimus: the OBLIQUE study (UK phase IV trial) JK Ramage, P Punia, O Faluyi, A Frilling, T Meyer, R Saharan, JW Valle Neuroendocrinology 108 (4), 317-327, 2019 | 20 | 2019 |
| Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre OO Faluyi, JL Connor, M Chatterjee, C Ikin, H Wong, DH Palmer British journal of cancer 116 (4), 424-431, 2017 | 19 | 2017 |
| NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts … MG McNamara, J Swain, Z Craig, R Sharma, OO Faluyi, J Wadsley, ... Journal of Clinical Oncology 40 (16_suppl), 4005-4005, 2022 | 16 | 2022 |
| A phase Ib study of NUC‐1031 in combination with cisplatin for the first‐line treatment of patients with advanced biliary tract cancer (ABC‐08) MG McNamara, J Bridgewater, DH Palmer, O Faluyi, H Wasan, A Patel, ... The oncologist 26 (4), e669-e678, 2021 | 16 | 2021 |
| Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome L Eng, AK Azad, X Qiu, QQ Kong, D Cheng, N Ying, A Tse, Q Kuang, ... Carcinogenesis 36 (9), 956-962, 2015 | 16 | 2015 |
| Health utility scores from EQ-5D and health-related quality of life in patients with esophageal cancer: a real-world cross-sectional study MK Doherty, Y Leung, J Su, H Naik, D Patel, L Eng, QQ Kong, F Mohsin, ... Diseases of the Esophagus 31 (12), doy058, 2018 | 15 | 2018 |
| NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU … Z Craig, J Swain, E Batman, J Wadsley, N Reed, O Faluyi, J Cave, ... BMJ open 10 (2), e034527, 2020 | 13 | 2020 |
| Validation of micro RNA pathway polymorphisms in esophageal adenocarcinoma survival OO Faluyi, L Eng, X Qiu, J Che, Q Zhang, D Cheng, N Ying, A Tse, ... Cancer Medicine 6 (2), 361-373, 2017 | 9 | 2017 |
| Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome GJ Korpanty, L Eng, X Qiu, OO Faluyi, DJ Renouf, D Cheng, D Patel, ... Oncotarget 8 (17), 28093, 2017 | 8 | 2017 |
